$0.44 EPS Expected for Integra Lifesciences Holdings (IART); Himax Technologies Ads (HIMX) Shorts Raised By 2.28%

July 25, 2017 - By Marie Mckinney

Analysts expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to report $0.44 EPS on July, 26 before the open.They anticipate $0.04 EPS change or 10.00% from last quarter’s $0.4 EPS. IART’s profit would be $32.85M giving it 31.36 P/E if the $0.44 EPS is correct. After having $0.39 EPS previously, Integra Lifesciences Holdings Corp’s analysts see 12.82% EPS growth. The stock increased 0.27% or $0.15 during the last trading session, reaching $55.19. About shares traded. Integra Lifesciences Holdings Corp (NASDAQ:IART) has risen 32.67% since July 25, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.

Himax Technologies Ads (NASDAQ:HIMX) had an increase of 2.28% in short interest. HIMX’s SI was 14.62M shares in July as released by FINRA. Its up 2.28% from 14.29 million shares previously. With 4.92M avg volume, 3 days are for Himax Technologies Ads (NASDAQ:HIMX)’s short sellers to cover HIMX’s short positions. The SI to Himax Technologies Ads’s float is 11.6%. The stock decreased 3.79% or $0.34 during the last trading session, reaching $8.62. About shares traded. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) has declined 20.28% since July 25, 2016 and is downtrending. It has underperformed by 36.98% the S&P500.

Investors sentiment decreased to 1.13 in 2016 Q4. Its down 0.21, from 1.34 in 2016Q3. It dived, as 37 investors sold Integra Lifesciences Holdings Corp shares while 58 reduced holdings. 29 funds opened positions while 78 raised stakes. 33.92 million shares or 4.02% more from 32.61 million shares in 2016Q3 were reported. Susquehanna Intl Gru Llp owns 79,922 shares. Independent Portfolio Consultants Inc has invested 0.34% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART). New York-based Bnp Paribas Arbitrage Sa has invested 0% in Integra Lifesciences Holdings Corp (NASDAQ:IART). Castleark Management Llc owns 176,089 shares for 0.48% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 783 shares or 0% of the stock. Blackrock Grp Inc has 61,430 shares for 0% of their portfolio. 20,896 were accumulated by Metropolitan Life Ny. Gemmer Asset Mngmt Limited invested in 0% or 46 shares. Blackrock Advisors Ltd Liability holds 0% or 16,281 shares in its portfolio. Lpl Financial Limited Liability Corp, a California-based fund reported 2,869 shares. Riverhead Mgmt Ltd Co has invested 0% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART). Northwestern Mutual Wealth holds 0% or 73 shares. Deutsche Comml Bank Ag reported 77,878 shares. Etrade Capital Ltd holds 0.02% or 5,327 shares in its portfolio. Neuberger Berman Group Limited Liability Corp holds 228,844 shares.

Integra LifeSciences Holdings Corporation is a medical technology company. The company has market cap of $4.12 billion. The Firm focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. It has a 65.41 P/E ratio. The Company’s divisions include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Among 12 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Integra Lifesciences Holdings Corp. had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) earned “Sector Perform” rating by RBC Capital Markets on Friday, January 13. On Friday, January 6 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) has “Equalweight” rating given on Thursday, June 2 by Barclays Capital. The rating was maintained by Barclays Capital on Friday, July 29 with “Equal Weight”. The rating was initiated by Citigroup with “Buy” on Thursday, November 12. As per Wednesday, June 7, the company rating was maintained by UBS. The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) earned “Hold” rating by Lake Street on Wednesday, August 26. Lake Street upgraded it to “Buy” rating and $92 target in Friday, October 28 report. The rating was upgraded by JP Morgan on Monday, August 3 to “Overweight”. Raymond James upgraded the shares of IART in report on Wednesday, July 29 to “Outperform” rating.

Among 12 analysts covering Himax Tech (NASDAQ:HIMX), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Himax Tech had 25 analyst reports since August 10, 2015 according to SRatingsIntel. On Thursday, September 29 the stock rating was initiated by Roth Capital with “Buy”. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, March 10. Rosenblatt downgraded the shares of HIMX in report on Friday, July 21 to “Sell” rating. The firm has “Neutral” rating by Robert W. Baird given on Monday, January 30. On Thursday, December 3 the stock rating was upgraded by Northland Capital to “Outperform”. The company was downgraded on Tuesday, February 7 by Morgan Stanley. Craig Hallum downgraded Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) on Tuesday, January 10 to “Hold” rating. Topeka Capital Markets maintained Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) on Friday, December 11 with “Buy” rating. Nomura downgraded the shares of HIMX in report on Monday, September 26 to “Neutral” rating. The firm earned “Neutral” rating on Wednesday, January 11 by Roth Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: